Article PDF
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Krammer, P. The tumor strikes back: New data on expression of the CD95(APO-1/Fas) receptor/ligand system may cause paradigm changes in our view on drug treatment and tumor immunology. Cell Death Differ 4, 362–364 (1997). https://doi.org/10.1038/sj.cdd.4400252
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/sj.cdd.4400252
This article is cited by
-
Weapons Ovarian Epithelial Tumors May Use in Immune Escape: An Immunohistochemical Correlational Study
Pathology & Oncology Research (2012)
-
Palmitoylation of human FasL modulates its cell death-inducing function
Cell Death & Disease (2010)
-
Tumor counterattack: fact or fiction?
Cancer Immunology, Immunotherapy (2005)
-
Sensitivity to TRAIL/APO-2L-mediated apoptosis in human renal cell carcinomas and its enhancement by topotecan
Cell Death & Differentiation (2000)
-
The molecular genetics of cervical carcinoma
British Journal of Cancer (1999)